Contribution of Soluble Forms of Programmed Death 1 and Programmed Death Ligand 2 to Disease Severity and Progression in Systemic Sclerosis
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Contribution of Soluble Forms of Programmed Death 1 and Programmed Death Ligand 2 to Disease Severity and Progression in Systemic Sclerosis
Authors
Keywords
-
Journal
Arthritis & Rheumatology
Volume 69, Issue 9, Pages 1879-1890
Publisher
Wiley
Online
2017-05-26
DOI
10.1002/art.40164
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Abnormal B Lymphocyte Activation and Function in Systemic Sclerosis
- (2015) Ayumi Yoshizaki et al. Annals of Dermatology
- Soluble PD-1 aggravates progression of collagen-induced arthritis through Th1 and Th17 pathways
- (2015) Cuiping Liu et al. ARTHRITIS RESEARCH & THERAPY
- PD-L1hi B cells are critical regulators of humoral immunity
- (2015) Adnan R. Khan et al. Nature Communications
- The PD-1/PD-Ls pathway and autoimmune diseases
- (2014) Suya Dai et al. CELLULAR IMMUNOLOGY
- Increased PD-1 on CD4+CD28− T cell and soluble PD-1 ligand-1 in patients with T2DM: Association with atherosclerotic macrovascular diseases
- (2013) Bimin Shi et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Aberrant production of soluble inducible T-cell co-stimulator (sICOS) and soluble programmed cell death protein 1 (sPD-1) in patients with chronic hepatitis C
- (2013) DONGSHENG WANG et al. Molecular Medicine Reports
- Increased soluble programmed death-1 (sPD-1) is associated with disease activity and radiographic progression in early rheumatoid arthritis
- (2013) SR Greisen et al. SCANDINAVIAN JOURNAL OF RHEUMATOLOGY
- IL-10-producing regulatory B cells (B10 cells) in autoimmune disease
- (2013) Ioannis Kalampokis et al. ARTHRITIS RESEARCH & THERAPY
- Regulatory B cells control T-cell autoimmunity through IL-21-dependent cognate interactions
- (2012) Ayumi Yoshizaki et al. NATURE
- Immunization with DNA topoisomerase I and Freund's complete adjuvant induces skin and lung fibrosis and autoimmunity via interleukin-6 signaling
- (2011) Ayumi Yoshizaki et al. ARTHRITIS AND RHEUMATISM
- Novel regulatory functions for Toll-like receptor-activated B cells during intracellular bacterial infection
- (2011) Simon Fillatreau IMMUNOLOGICAL REVIEWS
- Elevated serum interleukin-27 levels in patients with systemic sclerosis: association with T cell, B cell and fibroblast activation
- (2010) A. Yoshizaki et al. ANNALS OF THE RHEUMATIC DISEASES
- PD-1, gender, and autoimmunity
- (2010) Ravi K. Dinesh et al. AUTOIMMUNITY REVIEWS
- Characterization of a rare IL-10-competent B-cell subset in humans that parallels mouse regulatory B10 cells
- (2010) Y. Iwata et al. BLOOD
- Regulation of immunity and autoimmunity by B cells
- (2010) Claudia Mauri CURRENT OPINION IN IMMUNOLOGY
- Unexpected Acceleration of Type 1 Diabetes by Transgenic Expression of B7-H1 in NOD Mouse Peri-Islet Glia
- (2010) J. Yantha et al. DIABETES
- PD-L1 and PD-L2 differ in their molecular mechanisms of interaction with PD-1
- (2010) M. Ghiotto et al. INTERNATIONAL IMMUNOLOGY
- PD-1 regulates germinal center B cell survival and the formation and affinity of long-lived plasma cells
- (2010) Kim L Good-Jacobson et al. NATURE IMMUNOLOGY
- A micro-ELISA system for the rapid and sensitive measurement of total and specific immunoglobulin E and clinical application to allergy diagnosis
- (2009) Toshinori Ohashi et al. LAB ON A CHIP
- CD19 Regulates Skin and Lung Fibrosis via Toll-Like Receptor Signaling in a Model of Bleomycin-Induced Scleroderma
- (2008) Ayumi Yoshizaki et al. AMERICAN JOURNAL OF PATHOLOGY
- A Regulatory B Cell Subset with a Unique CD1dhiCD5+ Phenotype Controls T Cell-Dependent Inflammatory Responses
- (2008) Koichi Yanaba et al. IMMUNITY
- Clinical Significance of Serum HMGB-1 and sRAGE Levels in Systemic Sclerosis: Association with Disease Severity
- (2008) Ayumi Yoshizaki et al. JOURNAL OF CLINICAL IMMUNOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started